|
KMID : 0893420220230050078
|
|
Journal of Veterinary Science
2022 Volume.23 No. 5 p.78 ~ p.78
|
|
|
Antibacterial activity of florfenicol composite nanogels against Staphylococcus aureus small colony variants
|
|
Jinhuan Liu
Mujie Ju
Yifei Wu
Nannan Leng
Samah Attia Algharib
Wanhe Luo
|
|
|
Abstract
|
|
|
Background : Florfenicol might be ineffective for treating Staphylococcus aureus small colony variants (SCVs) mastitis.
Objectives : In this study, florfenicol-loaded chitosan (CS)-sodium tripolyphosphate (TPP) composite nanogels were prepared to allow targeted delivery to SCV infected sites.
Methods : The formulation screening, the characteristics, in vitro release, antibacterial activity, therapeutic efficacy, and biosafety of the florfenicol composite nanogels were studied.
Results : The optimized formulation was obtained when the CS and TPP were 10 and 5 mg/mL, respectively. The encapsulation efficiency, loading capacity, size, polydispersity index, and zeta potential of the optimized florfenicol composite nanogels were 87.3% ± 2.7%, 5.8% ± 1.4%, 280.3 ± 1.5 nm, 0.15 ± 0.03, and 36.3 ± 1.4 mv, respectively. Optical and scanning electron microscopy showed that spherical particles with a relatively uniform distribution and drugs might be incorporated in cross-linked polymeric networks. The in vitro release study showed that the florfenicol composite nanogels exhibited a biphasic pattern with the sustained release of 72.2% ± 1.8% at 48 h in pH 5.5 phosphate-buffered saline. The minimal inhibitory concentrations of commercial florfenicol solution and florfenicol composite nanogels against SCVs were 1 and 0.25 μg/mL, respectively. The time-killing curves and live?dead bacterial staining showed that the florfenicol composite nanogels were concentration-dependent. Furthermore, the florfenicol composite nanogels displayed good therapeutic efficacy against SCVs mastitis. Biological safety studies showed that the florfenicol composite nanogels might be a biocompatible preparation because of their non-toxic effects on the renal tissue and liver.
Conclusions : Florfenicol composite nanogels might improve the treatment of SCV infections.
|
|
|
KEYWORD
|
|
|
Florfenicol, Staphylococcus aureus small colony variants, antibacterial activity, therapeutic efficacy, biosafety
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
|
|
|